Risk Evaluation and Mitigation Strategy (REMS) Program

REMS Program Audits: Ensuring Safety and Compliance

The Risk Evaluation and Mitigation Strategy (REMS) Program is a critical initiative by the U.S. FDA to ensure the benefits of certain medications outweigh their risks.

For medications that come with serious safety concerns, adherence to REMS requirements is essential. Rephine’s REMS audits provide the assurance you need to meet these requirements effectively.

Rephine delivers specialised REMS audits to pharmacies and healthcare facilities in the USA, ensuring full compliance with FDA requirements.

Our audits go beyond GMP evaluations to focus on key aspects of REMS compliance, including:

Certification of prescribers, dispensers, and healthcare facilities.

Registry and tracking system evaluations.

Monitoring compliance and following up on Corrective and Preventive Actions (CAPA).

How Rephine Can Help

Rephine’s global team of experienced consultants offers tailored support to simplify REMS compliance:

Efficient Auditing: Conducting audits at scale to ensure comprehensive oversight.
CAPA Management: Providing guidance on CAPA planning and follow-up.
Program Management: Managing extensive audit schedules for large REMS product portfolios.

Guide: Partnering with a leading European pharmaceutical manufacturer, Rephine successfully completed 125 REMS audits in one year, ensuring strict adherence to FDA guidelines.

Why Choose Rephine?

With a proven track record in REMS compliance and a global team of experts, Rephine ensures:

Scalable audit capabilities.
Adherence to stringent FDA guidelines.
Streamlined processes for pharmacies, healthcare facilities, and manufacturers.

Need to discuss about a project? We are only one discovery call away.

Ensure your REMS compliance with Rephine’s trusted audit services. We offer free 30 minute discovery calls so we can understand your QA requirements for any project. Whether you're just starting out, or an established enterprise, we've got you covered.

The team at Rephine are incredibly professional. There’s no one we would trust in the same way with something as fundamental as the final quality of our product - and everything that has gone into it. It isn’t just that the Rephine team have all the right people in all the right places; it’s also that they’re also so deeply embedded in the regulatory environment that they always know what’s coming next, as well as what’s needed today.”

Where do you Need our Help?

For GMP Auditing, Quality Assurance & Digitalisation, we’re the partner of choice for all the stakeholders we deal with.

We provide extensive GMP consulting services to help keep our clients ahead of the needs and expectations of regulators.

Global Audit Library

Explore our extensive GMP audit library to see the range and scope of live reports we have in stock, join a live audit, or commission a bespoke audit

GMP Audit Services

Maintain high standards of life sciences manufacturing supplier qualifications and GMP auditing within the supply chain through our expertise

GxP Consultancy

Discover how we can help your product reach to market, fully and demonstrably complying with the latest GxP standards

Digitalisation

From data integrity to implementing new systems, our experienced team with a digital mindset, can lead you to transformative achievements

Related Resources

Guide

When Does Medical Software Qualify as a Medical Device? | MDR & IVDR Guide

Learn when medical software qualifies as a medical device under EU MDR & IVDR regulations. Explore classification rules, examples, and compliance tips for manufacturers.

Case Study

Navigating DMF Registration in China with Rephine

Explore case study showing the development of a project for a new pharmaceutical manufacturing plant with the objective to fulfill GMP requirements and minimise risks ...

Blog

Breaking into the Chinese Pharmaceutical Market: How to Successfully File a DMF

Learn how to navigate DMF submission in China with Rephine’s expert guidance. From compliance reviews to NMPA approval — streamline your entry into the Chinese ...

ICH E6 Guide Header Image (1500 x 844 px)

CSV

Understanding ICH E6 (R3): Good Clinical Practice and Computerised Systems Validation

The Guide for an Integrated Lifecycle Approach to Analytical Instrument Qualification and System Validation (AIQSV) is an essential resource for pharmaceutical laboratories striving to meet ...

Blog

AI Data Management & Governance: Best Practices for Compliance

In today’s fast-evolving regulatory landscape, maintaining compliance with Computer System Validation (CSV) and Data Integrity standards is more critical than ever. Organisations across the pharmaceutical, ...

Guide

Understanding Intended Purpose in EU MDR & IVDR: Key Implications for Medical Device Manufacturers

Our guide simplifies GSPR compliance, helping medical device companies meet EU safety standards, streamline CE marking, and get market-ready faster.

Guide

Why eQMS is Important? The Critical Role of eQMS in Modern Quality Management

Navigating the intricate landscape of implementing systems in Life Sciences Quality & R&D requires a strategic approach to the end-to-end

Guide

Understanding the UKCA Certification for Medical Devices

Navigating UKCA certification is essential for manufacturers seeking access to the Great Britain market. Understanding the regulatory landscape, transitional provisions, and compliance steps is key ...

Blog

Understanding Computer System Validation and Data Integrity Compliance

Let's get in touch

Please get in touch. Our expert GMP audit team is only a click away, on standby to answer all your questions.

Email: [email protected]

Social:

REPHINE HQ

Stevenage, UK
+44 1763 853135

REPHINE BARCELONA S.L.U

Barcelona, Spain
+34 934 178065

REPHINE CHINA

Shanghai, China

REPHINE INDIA

Hyderabad, India

First Name

Last Name

Phone

Country

Company

Job Title

Interested In

Message

Marketing Opt In

Rephine respects your privacy. Choosing to check the box means that you agree to the Rephine Privacy Policy. You can unsubscribe at any time.